XPOVIO™ (selinexor) Now Available to Excelera Network Members for Treatment of Relapsed or Refectory Multiple Myeloma

Tuesday, October 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

As part of the innovative treatments offered through the Excelera Network, members granted immediate access to XPOVIO upon the treatment's accelerated FDA approval in July 2019



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store